Effect on Metabolic Parameters of Abilify in SPR

Seoul National Hospital100 enrolled

Overview

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Schizophrenia Metabolic Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * DSM-IV diagnosis with schizophrenia * who signed an informed consent Exclusion Criteria: * comorbid with substance abuse or substance dependence * pregnancy or lactation

Locations (2)

Seoul National Hospital

Seoul, South Korea

RECRUITING

Seoul National Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose

Time frame: 1 year

Secondary Outcomes

prolactin ECG

Time frame: 1 year

Central Contacts

Shi Hyun Kang, MD

CONTACT

82-2-2204-0326 drshe@hanmail.net

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.